Clinical trials for Burkitt lymphoma
20 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPHASE1, PHASE2NCT07069699Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC GeneNational Cancer Institute (NCI) · PI: Sami Ibrahimi
- RECRUITINGEarly Phase 1NCT07429461Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic LeukemiaZhejiang University
- RECRUITINGEarly Phase 1NCT06793241Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic LeukemiaZhejiang University · PI: He Huang, MD
- RECRUITINGPHASE2, PHASE3NCT06764238Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL ProtocolInstitute of Hematology & Blood Diseases Hospital, China · PI: Xiaofan Zhu, MD
- RECRUITINGNCT06796517Immunotherapy in LymphomaSung-Soo Park
- RECRUITINGPhase 1NCT06060782Thiotepa, Cyclophosphamide, Clarithromycin and CytarabineFifth Affiliated Hospital, Sun Yat-Sen University
- RECRUITINGPhase 2NCT06179524CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALLBeijing Yongtai Ruike Biotechnology Company Ltd · PI: Xiaofan Zhu
- RECRUITINGPhase 1NCT06056752QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaAnhui Provincial Hospital · PI: Xiaoyu Zhu, Ph.D
- ACTIVE NOT RECRUITINGPhase 2NCT05263583Sepantronium Bromide for the Treatment of High-grade B-cell LymphomaCothera Bioscience, Inc · PI: Vernon Jiang, PhD
- RECRUITINGPHASE1, PHASE2NCT05480449Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)Stephan Grupp MD PhD · PI: Allison Barz Leahy, MD
- ACTIVE NOT RECRUITINGPhase 1NCT03962465Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALLUniversity of Virginia · PI: Michael Douvas, MD
- ACTIVE NOT RECRUITINGPhase 2NCT05460533A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)Memorial Sloan Kettering Cancer Center · PI: Kevin Curran, MD
- RECRUITINGPhase 2NCT06081478CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic LeukemiaBeijing Tongren Hospital
- RECRUITINGNCT04425421Recommendations for the Treatment of Children With Burkitt's LymphomaFrench Africa Pediatric Oncology Group
- ACTIVE NOT RECRUITINGPhase 1NCT04214886CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell MalignanciesLoyola University · PI: Nasheed Hossain, MD
- RECRUITINGPhase 3NCT04094311Study of Out of Specification for TisagenlecleucelNovartis Pharmaceuticals · PI: Novartis Pharmaceuticals
- ACTIVE NOT RECRUITINGPhase 2NCT03793140A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk TranslocationsMemorial Sloan Kettering Cancer Center · PI: Ariela Noy, MD
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT03504644Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic LeukemiaECOG-ACRIN Cancer Research Group · PI: Neil D Palmisiano
- RECRUITINGPhase 2NCT02981628Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic LeukemiaChildren's Oncology Group · PI: Maureen M O'Brien
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT02797470Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell TransplantAIDS Malignancy Consortium · PI: Mehrdad Abedi